journal article·2025-10Open access

Targeting Neutrophil/Eosinophil Extracellular Traps by Aptamer‐Functionalized Nanosheets to Overcome Recalcitrant Inflammatory Disorders

Yongqiang Xiao, Xinyue Wang, Ming Liu, Xiao Fu, Nanfeng Zhang, Wenqing Yang, Junyi Ge, Yangyang Li, Duan Ma, Jing Ma, Weiping Wen, Dongdong Ren, Tianyu Zhang, Zhaoxu Tu

Advanced Science· Volume 12· Issue 38

Abstract

Abstract Excessive generation of neutrophil extracellular traps (NETs) and eosinophil extracellular traps (EETs) can drive various inflammatory disorders by stimulating intracellular nucleic acid receptors. Although extracellular traps (ETs) are promising therapeutic targets for recalcitrant chronic inflammation, for example, otitis media with effusion (OME), practical and specific targeting of NETs/EETs in pathological tissues remains challenging. In this study, an ultrathin, 2D sheet‐like nanoscavenger C‐TA H is developed by modifying copper indium thiophosphate (CIPS) nanosheets with tannic acid (TA) and histone aptamers. The findings reveal that C‐TA H effectively binds the dsDNA of NETs/EETs, inhibits bacterial growth, and reduces reactive oxygen species (ROS) levels, leading to a depressed local inflammation in ovalbumin (OVA)‐induced OME rats. In addition, the therapeutic results also include reductions in inflammatory cytokines release, suppression of ETs‐activated danger signaling pathways, including toll‐like receptor 9 (TLR9) and nuclear factor‐kappa B (NF‐κB), as well as decreased mucous exudation and improved hearing functions. Comprehensively, transcriptomic analysis with RNA‐sequencing confirms that C‐TA H treatment significantly reverses the pathological gene expression changes after OVA sensitization. This work introduces an aptamer modification strategy for the target and capture of NETs/EETs, providing a potential therapeutic approach for modulating inflammatory signaling in OME as well as other recalcitrant inflammatory disorders.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Neutrophil, Myeloperoxidase and Oxidative Mechanisms · Immune Response and Inflammation · Antimicrobial Peptides and Activities

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

ENT Institute Department of Facial Plastic and Reconstructive Surgery Eye & ENT Hospital Fudan University Shanghai 200031 China

Department of Otolaryngology The Sixth Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510655 China

Department of Otology and Skull Base Surgery EYE and ENT Hospital of Fudan University Shanghai 200031 China

Department of ENT Second Affiliated Hospital of Anhui Medical University Hefei Anhui 230031 China

Key Laboratory of Metabolism and Molecular Medicine Ministry of Education Department of Biochemistry and Molecular Biology School of Basic Medical Sciences Fudan University Shanghai 200032 China

Department of Endocrinology Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 200021 China

Funding

National Natural Science Foundation of China · China Postdoctoral Science Foundation

References (82)

Show source-provided references
1. 10.1016/j.cytogfr.2024.12.00110.1016/j.cytogfr.2024.12.001 ↗
2. 10.3389/falgy.2024.144800710.3389/falgy.2024.1448007 ↗
3. 10.3390/microorganisms812192510.3390/microorganisms8121925 ↗
4. 10.3390/ijms24241726410.3390/ijms242417264 ↗
5. 10.1016/j.autrev.2017.09.01210.1016/j.autrev.2017.09.012 ↗
6. 10.1038/nm.195910.1038/nm.1959 ↗
7. 10.3389/fimmu.2023.129592110.3389/fimmu.2023.1295921 ↗
8. 10.3389/fimmu.2021.63695410.3389/fimmu.2021.636954 ↗
9. 10.1136/egastro-2024-10010410.1136/egastro-2024-100104 ↗
10. Harmes K. M. · Am. Fam. Physician · 2013 · 88 · 435
11. Nagar R. R. · Cureus · 2022 · 14
12. 10.3390/microorganisms1208152210.3390/microorganisms12081522 ↗
13. 10.1097/MAO.000000000000192910.1097/MAO.0000000000001929 ↗
14. 10.1136/bcr-2024-26231910.1136/bcr-2024-262319 ↗
15. Danishyar A. · 2024
16. 10.1159/00053792710.1159/000537927 ↗
17. 10.1007/s12070-020-01903-z10.1007/s12070-020-01903-z ↗
18. 10.3389/fmicb.2021.63404310.3389/fmicb.2021.634043 ↗
19. 10.1016/j.bbrc.2024.14989610.1016/j.bbrc.2024.149896 ↗
20. 10.1128/iai.00175-2410.1128/iai.00175-24 ↗
21. 10.1038/nrmicro241510.1038/nrmicro2415 ↗
22. 10.1073/pnas.190901711610.1073/pnas.1909017116 ↗
23. 10.1038/s41556-021-00762-210.1038/s41556-021-00762-2 ↗
24. 10.1038/s41578-022-00426-z10.1038/s41578-022-00426-z ↗
25. 10.1016/j.biomaterials.2020.12038910.1016/j.biomaterials.2020.120389 ↗
26. 10.1002/advs.20210374810.1002/advs.202103748 ↗
27. 10.1038/s41392-022-00950-y10.1038/s41392-022-00950-y ↗
28. 10.1016/j.matt.2021.09.00110.1016/j.matt.2021.09.001 ↗
29. 10.1021/acsami.4c1149410.1021/acsami.4c11494 ↗
30. Zhang Y. · Crit. Rev. Anal. Chem. · 2024 · 8 · 110.1080/10408347.2024.2401504 ↗
31. 10.1016/j.omtn.2024.10235810.1016/j.omtn.2024.102358 ↗
32. 10.1097/HS9.000000000000063310.1097/HS9.0000000000000633 ↗
33. 10.1038/s41565-022-01177-210.1038/s41565-022-01177-2 ↗
34. 10.1016/j.ccell.2020.12.01210.1016/j.ccell.2020.12.012 ↗
35. 10.1038/s41586-020-2394-610.1038/s41586-020-2394-6 ↗
36. 10.1038/s41419-021-03896-110.1038/s41419-021-03896-1 ↗
37. 10.1186/s12931-024-02923-x10.1186/s12931-024-02923-x ↗
38. 10.1007/s10238-021-00750-810.1007/s10238-021-00750-8 ↗
39. Zuo Y. · JCI Insight · 2020 · 5
40. 10.3389/fimmu.2021.80189710.3389/fimmu.2021.801897 ↗
41. 10.1097/MAO.000000000000312610.1097/MAO.0000000000003126 ↗
42. 10.1016/j.ijpharm.2017.03.05710.1016/j.ijpharm.2017.03.057 ↗
43. 10.1002/advs.20230780010.1002/advs.202307800 ↗
44. 10.1021/acsnano.3c1113910.1021/acsnano.3c11139 ↗
45. 10.1002/advs.20230527310.1002/advs.202305273 ↗
46. 10.1002/adma.20240355710.1002/adma.202403557 ↗
47. Xiao Y. Q. · Adv. Funct. Mater. · 2024 · 17
48. 10.1021/acsnano.8b0632110.1021/acsnano.8b06321 ↗
49. 10.1021/acs.iecr.0c0276610.1021/acs.iecr.0c02766 ↗
50. 10.1126/sciadv.aay714810.1126/sciadv.aay7148 ↗
51. 10.1038/s41467-022-33492-610.1038/s41467-022-33492-6 ↗
52. 10.1002/advs.20230527310.1002/advs.202305273 ↗
53. 10.1038/s41598-024-67498-510.1038/s41598-024-67498-5 ↗
54. 10.1007/s00405-022-07795-910.1007/s00405-022-07795-9 ↗
55. 10.1111/coa.1408610.1111/coa.14086 ↗
56. 10.1039/D3NR00349C10.1039/D3NR00349C ↗
57. 10.1038/s41598-018-34679-y10.1038/s41598-018-34679-y ↗
58. 10.1002/adma.20240685010.1002/adma.202406850 ↗
59. 10.1021/acsnano.1c0897010.1021/acsnano.1c08970 ↗
60. 10.1016/j.ijporl.2016.07.02510.1016/j.ijporl.2016.07.025 ↗
61. 10.2147/JMDH.S41411510.2147/JMDH.S414115 ↗
62. 10.1016/j.kint.2024.03.01010.1016/j.kint.2024.03.010 ↗
63. 10.1002/ctm2.179110.1002/ctm2.1791 ↗
64. 10.2147/JIR.S33859810.2147/JIR.S338598 ↗
65. 10.1080/00325481.2015.102831710.1080/00325481.2015.1028317 ↗
66. 10.1016/S0140-6736(18)31862-210.1016/S0140-6736(18)31862-2 ↗
67. 10.1016/j.amjoto.2024.10443910.1016/j.amjoto.2024.104439 ↗
68. 10.1097/AUD.000000000000131710.1097/AUD.0000000000001317 ↗
69. 10.1002/lary.2416610.1002/lary.24166 ↗
70. 10.1084/jem.2010023910.1084/jem.20100239 ↗
71. 10.3389/fimmu.2023.120652910.3389/fimmu.2023.1206529 ↗
72. Schorn C. · Front. Immunol. · 2012 · 3 · 277
73. 10.3389/fimmu.2018.0276310.3389/fimmu.2018.02763 ↗
74. 10.1007/s11882-016-0634-510.1007/s11882-016-0634-5 ↗
75. 10.1002/ctm2.117010.1002/ctm2.1170 ↗
76. 10.1073/pnas.230338512010.1073/pnas.2303385120 ↗
77. 10.1093/burnst/tkac04410.1093/burnst/tkac044 ↗
78. 10.1016/j.actbio.2023.11.02810.1016/j.actbio.2023.11.028 ↗
79. 10.1016/j.jconrel.2024.01.06810.1016/j.jconrel.2024.01.068 ↗
80. 10.1186/s40580-024-00414-910.1186/s40580-024-00414-9 ↗
81. 10.3390/ijms2202055910.3390/ijms22020559 ↗
82. 10.1067/mhn.2001.11914010.1067/mhn.2001.119140 ↗